Revolution Medicines (RVMD) EBITDA (2019 - 2025)
Historic EBITDA for Revolution Medicines (RVMD) over the last 7 years, with Q3 2025 value amounting to -$303.4 million.
- Revolution Medicines' EBITDA fell 10143.81% to -$303.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 billion, marking a year-over-year decrease of 6538.39%. This contributed to the annual value of -$599.3 million for FY2024, which is 3807.76% down from last year.
- According to the latest figures from Q3 2025, Revolution Medicines' EBITDA is -$303.4 million, which was down 10143.81% from -$264.7 million recorded in Q2 2025.
- Revolution Medicines' EBITDA's 5-year high stood at -$37.4 million during Q1 2021, with a 5-year trough of -$303.4 million in Q3 2025.
- For the 5-year period, Revolution Medicines' EBITDA averaged around -$123.8 million, with its median value being -$108.1 million (2023).
- As far as peak fluctuations go, Revolution Medicines' EBITDA plummeted by 1661.97% in 2022, and later crashed by 15948.76% in 2023.
- Over the past 5 years, Revolution Medicines' EBITDA (Quarter) stood at -$52.9 million in 2021, then fell by 16.62% to -$61.7 million in 2022, then plummeted by 159.49% to -$160.1 million in 2023, then decreased by 23.07% to -$197.1 million in 2024, then crashed by 53.96% to -$303.4 million in 2025.
- Its EBITDA was -$303.4 million in Q3 2025, compared to -$264.7 million in Q2 2025 and -$240.8 million in Q1 2025.